TFX Stock Analysis — Teleflex Incorporated
Sector: Healthcare
AI Verdict
TFX is cheap for the sector, but the low price reflects real doubts about its ability to reverse declining sales despite its hospital lock-in advantage.
Competitive Moat
Teleflex manufactures critical-care medical devices, with a defensible position in vascular access and anesthesia driven by regulatory barriers and hospital switching costs. Its broad product portfolio and embedded relationships with healthcare providers make it hard for new entrants to displace.
Summary
TFX trades at a 14.9x forward P/E, well below the healthcare sector median, after a year of shrinking sales.
Where It Stands
TFX's 14.9x forward P/E is a steep discount to the healthcare sector median of 22x, but it's paired with -14.5% revenue growth over the past year.
Key Metrics
- Forward P/E: 14.9x
- Revenue Growth: -0.1%
- Dividend Yield: 0.01%
- 52-Week High: $145.00
- 52-Week Low: $100.18
Analyst Consensus
8 Buy · 11 Hold · 0 Sell (19 analysts)
Bull Case
At 14.9x next year's earnings, you're paying a bargain price if Teleflex can stabilize sales and leverage its entrenched hospital relationships.
Bear Case
If the -14.5% revenue decline persists, even a low P/E could compress further, risking a value trap scenario.
Catalyst to Watch
Watch for upcoming earnings to see if revenue growth turns positive—any sign of stabilization could justify the current multiple.